Masako Tsurumaru

Eculizumab improves fatigue in refractory generalized myasthenia gravis

K. Patra, P. van Damme, M. Benatar, 2019, Quality of Life Research.

Effects of Tissue Pressure on Transgene Expression Characteristics via Renal Local Administration Routes from Ureter or Renal Artery in the Rat Kidney

S. Kawakami, M. Hashida, F. Yamashita, 2020, Pharmaceutics.

Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver After Local Administration in Mice

Hidefumi Mukai, M. Matsumoto, S. Mizukami, 2022, Journal of Pharmaceutical Sciences.

Evidence for the role of small ubiquitin-like modifier 4 as a general autoimmunity locus in the Japanese population.

K. Migita, K. Eguchi, H. Ikegami, 2006, The Journal of clinical endocrinology and metabolism.

Genetic heterogeneity in association of the SUMO4 M55V variant with susceptibility to type 1 diabetes.

T. Ogihara, S. Sugihara, Y. Hiromine, 2005, Diabetes.

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P. van Damme, M. Benatar, F. Piehl, 2019, Journal of the Neurological Sciences.

Synthesis and evaluation of a novel adapter lipid derivative for preparation of cyclic peptide-modified PEGylated liposomes: application of cyclic RGD peptide.

Hidefumi Mukai, Yuki Fuchigami, Masayori Hagimori, 2022, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Stability Study of mRNA-Lipid Nanoparticles Exposed to Various Conditions Based on the Evaluation between Physicochemical Properties and Their Relation with Protein Expression Ability

S. Kawakami, Hidefumi Mukai, Kazuma Yamashita, 2022, Pharmaceutics.

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

P. van Damme, M. Benatar, F. Piehl, 2020, Journal of Neurology.